Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The company's business focus is on the treatment of cancer, infections and autoimmune diseases. The research is based on the company's proprietary drug-delivery technology. The products are sold under separate brands and product development collaborations take place with other players in the industry. The company is headquartered in Uppsala.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Per Ahlström | 12,43 | 11,93 | 2026-03-27 |
| Investentia AB | 12,07 | 11,58 | 2026-03-27 |
| KSDR Hamberg AB | 8,65 | 8,30 | 2026-03-27 |
| Igor Lokot | 6,63 | 10,39 | 2026-03-27 |
| Avanza Pension | 3,63 | 3,49 | 2026-03-27 |
| Mushe Samunsson | 3,31 | 3,18 | 2026-03-27 |
| Carl Carvalho | 2,98 | 2,86 | 2026-03-27 |
| Magnus Hamberg | 2,91 | 2,80 | 2026-03-27 |
| Zaher Mahmoud Mirza | 1,75 | 1,68 | 2026-03-27 |
| Thomas Trumstedt | 1,62 | 1,55 | 2026-03-27 |
2026-05-22 Interim Report 2026-Q1
2026-08-27 Interim Report 2026-Q2
